Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

Wedbush analyst Yun Zhong maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $77 to $80.